Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Orexigen Therapeutics Inc. OREXQ

Healthcare Drug Manufacturers - Major
"Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity."

Recent & Breaking News (OTCPK:OREXQ)

46 Biggest Movers From Yesterday

Benzinga.com  March 13, 2018

Mid-Day Market Update: Dow Turns Negative; United Community Bancorp Shares Spike Higher

Benzinga.com  March 12, 2018

Orexigen Therapeutics Announces Third Quarter 2017 Financial Results

PR Newswire November 13, 2017

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin America

PR Newswire November 13, 2017

Earnings Scheduled For November 13, 2017

Benzinga.com  November 13, 2017

Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13, 2017

PR Newswire October 31, 2017

Orexigen Announces Favorable Decision from U.S. District Court in Patent Litigation, Confirming Exclusivity for Contrave Through 2030

PR Newswire October 13, 2017

Orexigen Therapeutics to Provide Business Update at the 2017 BIO Investor Forum

PR Newswire October 12, 2017

Orexigen Therapeutics Launches Next Stage of a Dynamic Campaign to Educate Consumers About Contrave®

PR Newswire September 26, 2017

Orexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 13, 2017

Orexigen Therapeutics to Speak at Upcoming Investor Conferences

PR Newswire August 29, 2017

Orexigen Therapeutics Announces Second Quarter 2017 Financial Results

PR Newswire August 8, 2017

Investor Network: Orexigen Therapeutics, Inc. to Host Earnings Call

Accesswire August 8, 2017

Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria

PR Newswire August 7, 2017

Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to Egypt

PR Newswire July 26, 2017

Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017

PR Newswire July 25, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  July 20, 2017

Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction

PR Newswire July 10, 2017

How These Drug Makers Stocks are Faring? -- Depomed, Pernix Therapeutics, United Therapeutics, and Orexigen Therapeutics

PR Newswire May 31, 2017

Orexigen Announces Activities at European Congress on Obesity 2017

PR Newswire May 16, 2017